An Open Label, Six-period Cross-over, Single and Repeat Dose Study to Determine the Pharmacokinetics of Fluticasone Furoate and GSK961081 When Administered Alone, in Combination, or Concurrently Via the ELLIPTA
Phase of Trial: Phase I
Latest Information Update: 22 May 2017
At a glance
- Drugs Batefenterol (Primary) ; Fluticasone furoate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 22 Aug 2016 Status changed from recruiting to completed.
- 18 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 12 Feb 2016 New trial record